Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Cash from Operations (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Cash from Operations data on record, last reported at 21545000.0 in Q4 2022.

  • For Q4 2022, Cash from Operations rose 71.43% year-over-year to 21545000.0; the TTM value through Dec 2022 reached 120982000.0, down 39.05%, while the annual FY2025 figure was 132031000.0, 2.56% up from the prior year.
  • Cash from Operations reached 21545000.0 in Q4 2022 per AVIR's latest filing, down from 21242000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 318521000.0 in Q4 2020 and bottomed at 75423000.0 in Q4 2021.
  • Average Cash from Operations over 3 years is 7395583.33, with a median of 17092500.0 recorded in 2021.
  • The widest YoY moves for Cash from Operations: up 338.4% in 2021, down 273.49% in 2021.
  • A 3-year view of Cash from Operations shows it stood at 318521000.0 in 2020, then plummeted by 123.68% to 75423000.0 in 2021, then soared by 71.43% to 21545000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 21545000.0 in Q4 2022, 21242000.0 in Q3 2022, and 19186000.0 in Q2 2022.